242 related articles for article (PubMed ID: 24443367)
21. Assessment of harms, benefits, and cost-effectiveness of prostate cancer screening: A micro-simulation study of 230 scenarios.
Getaneh AM; Heijnsdijk EAM; Roobol MJ; de Koning HJ
Cancer Med; 2020 Oct; 9(20):7742-7750. PubMed ID: 32813910
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of magnetic resonance imaging and targeted fusion biopsy for early detection of prostate cancer.
Barnett CL; Davenport MS; Montgomery JS; Wei JT; Montie JE; Denton BT
BJU Int; 2018 Jul; 122(1):50-58. PubMed ID: 29388388
[TBL] [Abstract][Full Text] [Related]
23. Comparative effectiveness of prostate cancer screening between the ages of 55 and 69 years followed by active surveillance.
de Carvalho TM; Heijnsdijk EAM; de Koning HJ
Cancer; 2018 Feb; 124(3):507-513. PubMed ID: 29231973
[TBL] [Abstract][Full Text] [Related]
24. Estimating the sensitivity of a prostate cancer screening programme for different PSA cut-off levels: A UK case study.
Leal J; Welton NJ; Martin RM; Donovan J; Hamdy F; Neal D; Noble S; Lane A; Wolstenholme J
Cancer Epidemiol; 2018 Feb; 52():99-105. PubMed ID: 29278842
[TBL] [Abstract][Full Text] [Related]
25. Cost implications of PSA screening differ by age.
Rao K; Liang S; Cardamone M; Joshu CE; Marmen K; Bhavsar N; Nelson WG; Ballentine Carter H; Albert MC; Platz EA; Pollack CE
BMC Urol; 2018 May; 18(1):38. PubMed ID: 29743049
[TBL] [Abstract][Full Text] [Related]
26. Economic Evaluation of Urine-Based or Magnetic Resonance Imaging Reflex Tests in Men With Intermediate Prostate-Specific Antigen Levels in the United States.
Jiao B; Gulati R; Hendrix N; Gore JL; Rais-Bahrami S; Morgan TM; Etzioni R
Value Health; 2021 Aug; 24(8):1111-1117. PubMed ID: 34372976
[TBL] [Abstract][Full Text] [Related]
27. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection.
Ross KS; Carter HB; Pearson JD; Guess HA
JAMA; 2000 Sep; 284(11):1399-405. PubMed ID: 10989402
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of prostate cancer screening: a systematic review of decision-analytical models.
Sanghera S; Coast J; Martin RM; Donovan JL; Mohiuddin S
BMC Cancer; 2018 Jan; 18(1):84. PubMed ID: 29347916
[TBL] [Abstract][Full Text] [Related]
29. Cost-Effectiveness of Magnetic Resonance Imaging in Prostate Cancer Screening: A Microsimulation Study.
Hao S; Karlsson A; Heintz E; Elfström KM; Nordström T; Clements M
Value Health; 2021 Dec; 24(12):1763-1772. PubMed ID: 34838274
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness analysis of anal cancer screening in women with cervical neoplasia in British Columbia, Canada.
Cromwell I; Gaudet M; Peacock SJ; Aquino-Parsons C
BMC Health Serv Res; 2016 Jun; 16():206. PubMed ID: 27349646
[TBL] [Abstract][Full Text] [Related]
31. Benefits, harms and cost-effectiveness of cancer screening in Australia: an overview of modelling estimates.
Lew JB; Feletto E; Wade S; Caruana M; Kang YJ; Nickson C; Simms KT; Procopio P; Taylor N; Worthington J; Smith D; Canfell K
Public Health Res Pract; 2019 Jul; 29(2):. PubMed ID: 31384886
[TBL] [Abstract][Full Text] [Related]
32. Screening for prostate cancer.
Ilic D; Neuberger MM; Djulbegovic M; Dahm P
Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD004720. PubMed ID: 23440794
[TBL] [Abstract][Full Text] [Related]
33. Cost-Effectiveness of the Stockholm3 Test and Magnetic Resonance Imaging in Prostate Cancer Screening: A Microsimulation Study.
Hao S; Heintz E; Östensson E; Discacciati A; Jäderling F; Grönberg H; Eklund M; Nordström T; Clements MS
Eur Urol; 2022 Jul; 82(1):12-19. PubMed ID: 35094896
[TBL] [Abstract][Full Text] [Related]
34. The socioeconomic implications of prostate-specific antigen screening.
Benoit RM; Naslund MJ
Urol Clin North Am; 1997 May; 24(2):451-8. PubMed ID: 9126243
[TBL] [Abstract][Full Text] [Related]
35. Current and projected annual direct costs of screening asymptomatic men for prostate cancer using prostate-specific antigen.
Krahn MD; Coombs A; Levy IG
CMAJ; 1999 Jan; 160(1):49-57. PubMed ID: 9934343
[TBL] [Abstract][Full Text] [Related]
36. Re: Cost-Effectiveness of Prostate Cancer Screening: A Simulation Study Based on ERSPC Data.
Taneja SS
J Urol; 2015 Jul; 194(1):113-4. PubMed ID: 26088223
[No Abstract] [Full Text] [Related]
37. Re: Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.
Noordzij MA; Blanker MH
J Natl Cancer Inst; 2015 Jun; 107(6):djv110. PubMed ID: 25888716
[No Abstract] [Full Text] [Related]
38. Clarifying the Trade-Offs of Risk-Stratified Screening for Prostate Cancer: A Cost-Effectiveness Study.
Hendrix N; Gulati R; Jiao B; Kader AK; Ryan ST; Etzioni R
Am J Epidemiol; 2021 Oct; 190(10):2064-2074. PubMed ID: 34023874
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of percent free PSA for prostate cancer detection in men with a total PSA of 4-10 ng/ml.
Bermúdez-Tamayo C; Martín Martín JJ; González Mdel P; Pérez Romero C
Urol Int; 2007; 79(4):336-44. PubMed ID: 18025853
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of lung cancer screening with low-dose computed tomography in heavy smokers: a microsimulation modelling study.
Du Y; Sidorenkov G; Heuvelmans MA; Groen HJM; Vermeulen KM; Greuter MJW; de Bock GH
Eur J Cancer; 2020 Aug; 135():121-129. PubMed ID: 32563896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]